Intellective Bio Files for HKEX Listing, No.2 in China’s Biologics CDMO by Number of Commercialized Products
NewTimeSpace News: Intellective Biologics (Suzhou) Co., Ltd. submitted a Main Board listing application to HKEX on June 1, with Dongxing Securities (Hong Kong) as the sole sponsor. Per Frost & Sullivan, the company ranked second among China’s biologics CDMOs by the number of commercialized products in 2025, and third by revenue among CDMOs focused on therapeutic antibody drugs.
NewTimeSpace News: As disclosed by HKEX, Intellective Biologics (Suzhou) Co., Ltd. filed for Main Board listing on June 1, 2026, with Dongxing Securities (Hong Kong) appointed sole sponsor.
A leading production-focused full-lifecycle CDMO specializing in biologics, the firm provides end-to-end CDMO services including process development, analytical method development & validation, GMP-compliant manufacturing, quality management and regulatory affairs. According to Frost & Sullivan, it secured the second position across China’s biologics CDMO sector by count of 2025 commercialized products and ranked third by revenue within the therapeutic antibody CDMO segment.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
